Results for: BioNTech

Goldman Sachs has upgraded BioNTech (BNTX) to Buy, citing the company’s BNT327, an immuno-oncology asset in clinical development. Data from Summit Therapeutics and Akeso for ivonescimab (PD-1xVEGF bispecific) has shown potential to challenge standard-of-care regimens across various solid tumors, sparking interest in BioNTech’s bispecific drug. Goldman analysts believe BNT327 has the potential to drive BioNTech toward becoming a leading player in oncology, making current stock levels an attractive entry point for investors.

BioNTech SE, the leading COVID-19 vaccine developer, has announced strong third-quarter revenue growth, driven by the earlier approval of its variant-adapted vaccines compared to the previous year. The company’s net profit and earnings per share also saw significant increases, highlighting its continued success in the evolving pandemic landscape.

Pfizer and BioNTech’s combined mRNA vaccine for influenza and COVID-19 has shown mixed results in a Phase 3 trial. While it met one of its primary immunogenicity objectives, it demonstrated lower responses against the influenza B strain compared to a licensed flu vaccine. The companies are evaluating adjustments to improve the vaccine’s effectiveness.

Moderna Inc. has filed a patent infringement lawsuit against Pfizer Inc. and BioNTech SE in a London court, alleging that the companies’ COVID-19 vaccine infringes on Moderna’s mRNA technology patents. Pfizer and BioNTech have denied the allegations and asserted that their patent is invalid. The outcome of the lawsuit could have significant implications for the mRNA vaccine market and the future of mRNA-based products.

Vaccine giants Pfizer and Moderna are embroiled in a legal battle over the use of mRNA technology in their respective Covid-19 vaccines. The dispute has sparked parallel litigation in multiple countries, with Moderna accusing Pfizer and its partner BioNTech of patent infringement. Pfizer and BioNTech deny the allegations and seek to revoke Moderna’s patents. The trial in the London High Court is expected to last three and a half weeks and focus on the validity of two Moderna patents.